3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
3
Vipoma
2
Somatostatinoma
2
Neuroblastoma
2
Neoplasms
2
Insulinoma
2
Glucagonoma
2
Gastrinoma
2
Colonic Neoplasms
2
Carcinoma, Islet Cell
2
Testicular Neoplasms
1
Teratoma
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Ovarian Germ Cell Cancer
1
Osteosarcoma
1
Optic Nerve Glioma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Neoplasms
1
Lung Neoplasms
1
Hepatoblastoma
1
Gastrointestinal Stromal Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gallbladder Neoplasms
1
Familial ependymoma
1
Fallopian Tube Neoplasms
1
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Oxaliplatin
×
Endocrine
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled